Vesugen 20mg
Janoshik
Batch VESU-CA-26G-20
Vesugen
Peptide Bioregulator
Also known as Lys-Glu-Asp (KED)
Vesugen is the tripeptide Lys-Glu-Asp, studied in research on vascular endothelium and age-related vascular change.
Mix & Match
1 vial — no vial discount yet.
Add 2 more vials for 5% off.
After that, 10% at 5 vials, 20% at 10 vials.
This product is intended strictly for laboratory research use within the United States. It is not approved by the FDA for the diagnosis, treatment, cure, or prevention of any disease. Not for human or veterinary use.
By purchasing, you confirm the material will be used solely for lawful research purposes in accordance with applicable U.S. federal, state, and local regulations.
Vesugen is the tripeptide Lys-Glu-Asp, studied in research on vascular endothelium and age-related vascular change.
Experimental work examines endothelial cell proliferation and vasoprotective endpoints under controlled conditions.
Vesugen is a three-residue peptide investigated within the vascular arm of the short-peptide bioregulator literature. Published work has examined molecular aspects of KED activity in atherosclerosis and restenosis models, and epigenetic aspects of peptidergic regulation of vascular endothelial cell proliferation during ageing.
More recent review work places the peptide within research on the senescence-associated secretory phenotype in cardiovascular cells.
Vesugen was characterized as the vascular-directed member of a family of short peptides differing by one or two residues.
Research from the 2010s focused on endothelial proliferation and vascular ageing, connecting the compound to the inflammaging literature.
Research into the KED sequence focuses on vascular endothelial proliferation and vasoprotective endpoints during ageing. Frameworks evaluate atherosclerosis and restenosis models, epigenetic regulation, and senescence-associated signaling in cardiovascular cells.
4 of the 4 areas below are addressed directly by a paper cited on this page.
Vascular endothelium proliferation models
Addressed on this page by Khavinson 2014, Khavinson 2022. Each is linked to its source record in the references below, so what was measured — and in what system — can be read rather than taken on trust.
- Khavinson, VKh. et al. (2014) — Epigenetic aspects of peptidergic regulation of vascular endothelial cell proliferation during aging
- Khavinson, V. et al. (2022) — Senescence-Associated Secretory Phenotype of Cardiovascular System Cells and Inflammaging: Perspectives of Peptide Regulation
Atherosclerosis and restenosis research
Addressed on this page by Kozlov 2016. Each is linked to its source record in the references below, so what was measured — and in what system — can be read rather than taken on trust.
- Kozlov, KL. et al. (2016) — Molecular aspects of vasoprotective peptide KED activity during atherosclerosis and restenosis
Epigenetic regulation of vascular ageing
Addressed on this page by Khavinson 2014, Khavinson 2022. Each is linked to its source record in the references below, so what was measured — and in what system — can be read rather than taken on trust.
- Khavinson, VKh. et al. (2014) — Epigenetic aspects of peptidergic regulation of vascular endothelial cell proliferation during aging
- Khavinson, V. et al. (2022) — Senescence-Associated Secretory Phenotype of Cardiovascular System Cells and Inflammaging: Perspectives of Peptide Regulation
Senescence and inflammaging frameworks
Addressed on this page by Khavinson 2022. Each is linked to its source record in the references below, so what was measured — and in what system — can be read rather than taken on trust.
- Khavinson, V. et al. (2022) — Senescence-Associated Secretory Phenotype of Cardiovascular System Cells and Inflammaging: Perspectives of Peptide Regulation
The references section of this page cites 3 primary papers published between 2014 and 2022 — a thin record. Every citation is linked to its PubMed or DOI record so it can be read rather than taken on trust, and the summaries above describe what those papers report rather than what the compound is claimed to do.
Research compounds attract claims that outrun their evidence. Below are the ones most often encountered for Vesugen, set against what the papers cited on this page actually report. Where the record is thin or contested, that is stated rather than smoothed over.
Vesugen is commonly described online in connection with slowing ageing and extending lifespan. In the research literature the same compound is filed under vascular endothelium proliferation models, atherosclerosis and restenosis research and epigenetic regulation of vascular ageing.
The 3 papers cited on this page, published between 2014 and 2022 (1 review) describe laboratory and animal work. None reports a controlled trial in humans. Findings in cell culture or in a rodent model describe what happened in that system; they do not establish that the same occurs in humans, and this compound is not approved for human use.
Nothing above is a statement of what this material does. It is a summary of what has been published and what has not. Eppix Labs supplies research materials only and provides no dosing, administration or protocol guidance.
Verification for Vesugen is per lot, not per product. The current 20mg lot VESU-CA-26G-20 returned 99.857% purity, 21.04 mg measured, 105.2% of the labelled 20 mg, assayed by Janoshik. Those figures are the laboratory's, published in full rather than reduced to a badge.
Purity is half the number. It states what fraction of the material in the vial is Vesugen; it says nothing about how much material is in the vial, and a short-filled vial can return a purity result that is entirely accurate. The figure that answers the second question is measured mass against expected content — for Vesugen, this lot measured 105.2% of its labelled 20 mg. Both numbers are published for every lot, whichever way they fall.
The lot code printed on the vial matches the code on the certificate for Vesugen. Matching the two is what confirms the unit in hand came from the batch that was tested — a certificate not tied to a lot code proves nothing about any particular unit.
Researchers who buy Vesugen in the United States through Eppix Labs receive the lot described by the certificate above: the code printed on the vial label is the code on the certificate, and both are searchable on the batch verification page.
- Lyophilized storage
- −20 °C long-term; stable at room temperature in transit
- After reconstitution
- 2–8 °C
- Light
- Protect from UV and direct light
- Freeze-thaw
- Avoid repeated cycles
- Vehicle
- Bacteriostatic water in most published protocols
- Format
- Lyophilized powder
Vesugen is supplied as lyophilized powder. In the dry state the material is comparatively stable, which is why it ships at ambient temperature without a cold chain; once reconstituted it is a peptide in solution and the handling constraints tighten considerably. At 3 residues it is short enough to be produced by solid-phase synthesis, and the published sequence on this page is what an identity assay is checked against.
Repeated freeze-thaw cycling is the handling error most likely to degrade material of this class, because each cycle concentrates solutes at the ice boundary. Where a protocol calls for the same vial across multiple sessions, the published literature generally describes aliquoting after reconstitution rather than re-freezing the whole volume.
Vials may appear empty on arrival. Lyophilized material collects at the base of the vial and is often not visible until the vial is inspected under direct light.
- 1 × sealed glass vial in the strength selected (20mg / Single Vial, 20mg / 5-Pack, 20mg / 10-Pack available), batch-labelled
- The batch-linked Certificate of Analysis for the exact lot shipped
- Discreet outer packaging with no product names on the exterior
- FedEx, tracked, typically 1–3 business days domestically
- Bacteriostatic water or any other reconstitution vehicle
- Syringes, needles or filters
- Dosing, administration or protocol guidance of any kind
Reconstitution materials are sourced separately. The reconstitution calculator on this site works out concentrations for a given volume, but it is an arithmetic tool for laboratory record-keeping and not a protocol.
No. Eppix Labs products are supplied exclusively for laboratory research. We do not provide dosing, administration, or usage guidance.
Each unit contains the labeled quantity of Vesugen. Independent third-party analysis verifies purity, identity, and net content per batch.
The unit contains only the research compound. Any laboratory materials required for reconstitution or experimental procedures must be sourced separately.
Duration depends entirely on research design, storage conditions, and laboratory protocol.
Molecular aspects of vasoprotective peptide KED activity during atherosclerosis and restenosis
PubMedEpigenetic aspects of peptidergic regulation of vascular endothelial cell proliferation during aging
PubMedSenescence-Associated Secretory Phenotype of Cardiovascular System Cells and Inflammaging: Perspectives of Peptide Regulation
PubMedRelated
You May Also Like
Next-generation GLP receptor agonist studied for metabolic signaling and nutrient partitioning pathways
From$79.99
Dual incretin receptor agonist studied for glucose regulation, metabolic signaling, and weight pathway research
From$39.99
Studied in metabolic research for its effects on glucose regulation, appetite signaling, and energy balance.
From$59.99
Long-acting amylin analog engineered for appetite signaling, metabolic control, and energy balance research
From$99.99